ABSTRACT
Objective To explore the expression of Aurora-A in breast carcinoma and the relationship with breast carcinoma treatment efficacy of paclitaxel. Methods The expression of Aurora-A were tested by immunohistochemical SP method in 67 cases of breast carcinoma. The relationship of Aurora-A with treatment efficacy of paclitaxel was analysed. Results The expression rate of Aurora-A was 73.13%(49/67)in breast carcinoma. The treatment effective rate of breast carcinoma was 77.78%(14/18) and the rate of nonresponder was 11.11%(2/18) in negative expression of Aurora-A;but the treatment effective rate was 34.69%(17/49) and the rate of nonresponder was 34.69%(17/49) in positive expression of Aurora-A. There were obvious correlations between expression of Aurora-A and treatment efficacy of paclitaxel. Statistical significance could be found between them (P = 0.013 ). Conclusion There is manifest correlation between the high expression of Aurora-A and resistance of paclitaxel in breast carcinoma.
ABSTRACT
Objective To observe and cpmpare the efficacy and complications of hyperfractional integrated intraeavitary brachtherapy in middle-advanced squamous-cell carcinoma with the traditionsl brachytherapy.Methods In the observed group,328 patients with cervical cancer received hypeffractional integrated intracavitary after loading therapy between Jan 2004 and Jan 2005 were selected.The dose of point A was 2.5 Gy-3.0 Gy/fraction,2 fractions per week,and the total dose of reference point A was 49.8 Gy in stage Ⅱ b,52.6 Gy in stage in Ⅲb.In the control group,331 cases treated with traditional aflerloading brachytherapy between Jan 2002 and Dec 2003 were selected.The dose of point A was 5.0～7.0 Gy/fraction,1 fraction per week,and the total dose of point A was 50.1 Gy in stage Ⅱb,53.5 Gy in stage Ⅲb.In vitro irradiation began at the same time with the intracavitary brachytherapy.The whole pelvic was irradiated with 15 MV X-rays.Results In the observed group,the recent control rate of stage Ⅱb was 97.2%(104/107),94.1%(208/221)for stage Ⅲb.The 3-year survival rate was 80.5%(264/328).and the 5-year survival rate was 68.6%(225/328).The complication rate was 5.2%(17/328)for cystitis, 14.6%(48/328) for proctitis.Out of 331 cases in control group,the recent control rate of stage Ⅱb was 95.4%(103/108),92.8%(207/223)for stage Ⅲb.The 3-year survival rate was 75.2%(249/331),the 5-vear survival rate was 62.5%(207/331).The complication rate was 13.3%(44/331)for cystitis,and 32.3%(107/331)for proctitis.Conclusions Compared with combination of traditional brachytherapy and external radiotherapy,combination of hyperfraetional integrated brachtherapy therapy and external radiotherapy has no significant improvement for recent control rate and long-term survival rate,but could reduce the complication rates of cystitis and proctitis.